- Home
- SLRX vs SONN Comparison
SLRX vs SONN Comparison
Compare SLRX & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- SONN
- Stock Information
- Founded
- SLRX N/A
- SONN N/A
- Country
- SLRX United States
- SONN United States
- Employees
- SLRX N/A
- SONN N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- SLRX Health Care
- SONN Health Care
- Exchange
- SLRX Nasdaq
- SONN Nasdaq
- Market Cap
- SLRX 2.1M
- SONN 2.5M
- IPO Year
- SLRX N/A
- SONN N/A
- Fundamental
- Price
- SLRX $1.70
- SONN $1.75
- Analyst Decision
- SLRX
- SONN Strong Buy
- Analyst Count
- SLRX 0
- SONN 2
- Target Price
- SLRX N/A
- SONN $38.00
- AVG Volume (30 Days)
- SLRX 98.7K
- SONN 2.8M
- Earning Date
- SLRX 11-14-2024
- SONN 12-17-2024
- Dividend Yield
- SLRX N/A
- SONN N/A
- EPS Growth
- SLRX N/A
- SONN N/A
- EPS
- SLRX N/A
- SONN N/A
- Revenue
- SLRX N/A
- SONN $18,626.00
- Revenue This Year
- SLRX N/A
- SONN N/A
- Revenue Next Year
- SLRX N/A
- SONN N/A
- P/E Ratio
- SLRX N/A
- SONN N/A
- Revenue Growth
- SLRX N/A
- SONN N/A
- 52 Week Low
- SLRX $1.22
- SONN $1.41
- 52 Week High
- SLRX $7.20
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- SLRX 56.15
- SONN 39.88
- Support Level
- SLRX $1.52
- SONN $1.41
- Resistance Level
- SLRX $2.06
- SONN $1.54
- Average True Range (ATR)
- SLRX 0.18
- SONN 0.17
- MACD
- SLRX 0.03
- SONN 0.09
- Stochastic Oscillator
- SLRX 57.14
- SONN 57.63
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.